November 17, 2024 10:31am
A scorecard of earnings releases of covered companies
Reporting to date - 34
The current LPS (loss per share) or net income, revenue, cash positions i.e. "runways" is a reflection of this universe's investing "status".
|
COMPANY |
SYMBOL |
NET INCOME |
Q2/24 LOSS & LPS |
Revenue |
CASH POSITION | RUNWAY |
|---|---|---|---|---|---|---|
|
Blueprint Medicine |
BPMC |
|
-$56.3 M -$$0.53 per share |
$218.2 M w/costs of -$1.9 M |
$882.4 M | 2027 |
|
Agenus
|
AGEN
|
-$67 M or -$3.17 per share |
$25 M | $44.8 M | 2025 | |
|
Alnylam Pharmaceuticals |
ALNY
|
-$111.6 M or -$0.87 per share |
$420 M | $2.78 B | 2027 | |
| Prime Medicine |
PRME |
-$52.5 M or -$0.44 per share |
$55 M | $244.6 M | 1H/26 | |
|
Adverum Biotechnologies |
ADVM
|
-$27 M or -$1.30 per share |
$1 M | $153.2 M | 2026 | |
|
Compass Therapeutics
|
CMPX |
-$10.5 M or -$0.08 per share |
0 | $135 M | Q1/27 | |
|
AxoGen |
AXGN
|
-$1.9 M or -$0.04 per share |
$48.6 M | $30.5 | 2026 | |
|
Generation Bio |
GBIO |
|
-$15.3 M or -$0.23 per share |
0 | $199.8 M | 2H/2027 |
|
Beam Therapeutics |
BEAM |
|
-$96.7 M or -$1.17 per share |
$14.2 M | $925.8 M | 2027 |
|
BioLife Solutions |
BLFS
|
|
-$1.7 M or -$0.04 per share |
$30.6 M |
$39.3 M w/sale of sub SciSafe for $73 M |
2027 |
| Harvard Apparatus RT |
OTCQB: HRGN |
-$1.8 M or -$0.12 per share |
$59 K | $3.59 M | Q2/25 | |
|
bluebird bio
|
BLUE
|
|
-$60.8 M or -$0.31 per share |
$10.6 M | $118.7 M | 2025 |
|
Brainstorm Cell Therapeutics
|
BCLI |
-$2.7 M or -$0.51 per share |
0 | $35 K | Q4/24 | |
|
Caribou Biosciences |
CRBU |
-$34.1 M or -$0.38 per share |
$2 M | $281 M | 2026 | |
| Cellectis SA |
CLLS
|
|
-$23 M or -$0.31 per share |
$18.05 M | $264 M | Q1/26 |
|
CRISPR Therapeutics |
CRSP
|
|
-$85.9 M or -$1.01 per share |
$11.2 M | $1.9 B | 2027 |
|
Editas Medicine |
EDIT
|
|
-$62.2 M or -$0.75 per share |
$1 K | $265.1 M | 2Q/2026 |
|
Fate Therapeutics |
FATE
|
-$47.67 M or -$0.40 per share |
$3.1 M | $330.5 M | Q4/25 | |
|
Lenz Therapeutics Formerly Graphite Bio |
LENZ |
|
-$10.2 M or -$0.39 per share |
$139.4 M | $217.2 M | 2027 |
|
|
|
|||||
|
Intellia Therapeutics |
NTLA
|
-$135.7 M or -$1.34 per share |
$9.1 M |
$944.7 M (ATM $176.9 M & $47 M collab/reimb) |
2026 | |
|
Precigen |
PGEN
|
-$23.97 M or -$0.09 per share |
$953 K | $24.7 M | 2025 | |
|
Ionis Pharmaceuticals |
IONS
|
|
-$140 M or -$0.95 per share |
$134 M | $2.5 B | 2027 |
| Mesoblast |
MESO
|
N/A |
N/A | $51.1 M | 2026 | |
| MiMedx Group |
MDXG
|
+$8.095 M or +$0.05 per share |
|
$84 M $69 M gross profit |
$89 M | 2026 |
|
Verve Therapeutics |
VERV |
-$50.1 M or -$0.59 per share |
$6.9 M | $539.9 M | 2026 | |
|
Regenxbio
|
RGNX
|
|
-$59.6 M or -$1.17 per share |
$24.2 M | $278.6 M | 2026 |
|
Sage Therapeutics |
SAGE
|
-$96.3 M or -$0.53 per share |
$11 M w/costs of -$5.3 M |
$569 M | 2027 | |
|
Sangamo Biosciences |
SGMO
|
+$10.7 M or +0.04 per share |
|
$49.4 M | $39.2 | Q1/25 |
|
Solid Biosciences |
SLDB
|
-$32.7 M or -$0.79 |
0 | $171 M | 2026 | |
|
Ultragenyx Pharmaceuticals |
RARE |
-$133.5 m or -$1.40 per share |
$39.4 M | $825 M | 2027 | |
|
uniQure N.V.
|
QURE
|
|
-$44.4 M or -$0.91 per share |
$2.3 M |
$435 M w/-$50 M debt |
2026 |
|
Moderna |
MRNA |
+$13 M or +$0.03 per share |
|
$1.86 B | $9.2 B | N/A |
|
Vericel
|
VCEL
|
|
-$900 K or -$0.02 per share |
$57.9 M | $151 M | 2027 |
|
Voyager Therapeutics |
VYGR
|
|
-$9 M or -$0.16 per share |
$24.6 M |
$345 M +18 M from NVS & NBIX |
Q4/2026 |
